drugset
drugset / Trial / NCT05005520

Study of DTRI-031 in Healthy Volunteers

NCT05005520 ↗

Phase 1 Completed 46 enrolled Basking Biosciences, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, single center, placebo-controlled phase 1 study in healthy volunteers to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single intravenous (iv) injection of DTRI-031

Timeline

Start
2021-10-20
Primary completion
2022-04-19
Completion
2022-04-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator DTRI-031 Unknown — Intravenous

Indications

No indication recorded.